首页> 外文期刊>Journal of aerosol medicine and pulmonary drug delivery >Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration
【24h】

Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration

机译:海藻糖和亮氨酸的喷雾干燥型流感抗原产生可雾化的粉状疫苗配方,在肺部给药后可诱导强大的全身和粘膜免疫力

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Pulmonary immunization has recently gained increased interest as a means to induce both systemic and mucosal immunity while eliminating issues associated with the use of needles in parenteral vaccination. However, in contrast to the inhaled delivery of small molecule drugs, a dry powder carrier platform that is readily adaptable to the incorporation of biomacromolecules (e.g., vaccine antigens) as a common standard is lacking. Spray-dried trehalose with leucine has previously been characterized and demonstrated to produce highly aerosolizable powders containing an amorphous glassy matrix suitable for stabilization of biomacromolecules. This study aimed to further extend the understanding in the use of this formulation as a dry powder carrier platform in an in vivo setting, using influenza antigen as a model, for pulmonary delivery of biomacromolecules. Methods: Spray-dried influenza vaccine was produced using previously established spray-drying conditions. The formulations were characterized to examine the impact of influenza antigen on the solid-state properties of the spray-dried powders. The optimal vaccine formulation was then selected for in vivo immunogenicity study in rats to evaluate the efficacy of the reconstituted spray-dried vaccine compared to liquid vaccine administered via pulmonary and subcutaneous routes. Results: The formation of amorphous glassy matrix and morphology of the spray-dried particles, within the protein concentration range used in the study, was not affected by the incorporation of the influenza antigen. However, the amount of proteins incorporated increased water content and reduced the glass transition temperature (T-g) of the formulation. Nevertheless, the spray-dried vaccine induced strong mucosal and systemic immunity comparable to liquid vaccine after pulmonary and subcutaneous immunization without causing any inflammation to the lung parenchyma. Conclusions: The study demonstrated the usability of the spray-dried carrier as a promising platform for pulmonary delivery of influenza vaccine. The potential utility of this delivery system for other biomacromolecules may also be further explored.
机译:背景:肺部免疫最近引起了人们的兴趣,因为它既可以诱导全身和粘膜免疫,又可以消除与在肠胃外疫苗接种中使用针头相关的问题。然而,与小分子药物的吸入递送相反,缺乏一种干粉载体平台,其容易适应作为通用标准的生物大分子(例如疫苗抗原)的掺入。先前已对亮氨酸喷雾干燥的海藻糖进行了表征,并证明可生产出高度雾化的粉末,该粉末含有适合稳定生物大分子的无定形玻璃状基质。这项研究旨在进一步扩大对这种制剂作为体内干粉载体平台的理解,以流感抗原为模型,用于体内生物大分子的肺部递送。方法:使用先前确定的喷雾干燥条件生产喷雾干燥的流感疫苗。对该制剂进行表征,以检查流感病毒抗原对喷雾干燥粉末固态特性的影响。然后选择最佳疫苗制剂用于大鼠体内免疫原性研究,以评估与通过肺部和皮下途径给药的液体疫苗相比,重组喷雾干燥疫苗的功效。结果:在研究使用的蛋白质浓度范围内,无定形玻璃状基质的形成和喷雾干燥颗粒的形态不受流感抗原掺入的影响。然而,掺入的蛋白质的量增加了水含量并降低了制剂的玻璃化转变温度(T-g)。尽管如此,经喷雾干燥的疫苗在进行肺和皮下免疫后仍可产生与液体疫苗相当的强粘膜和全身免疫性,而不会引起肺实质的任何炎症。结论:该研究证明了喷雾干燥载体作为肺部接种流感疫苗的有希望的平台的可用性。还可以进一步探索该递送系统对其他生物大分子的潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号